FOUNDAYO Film-coated tablet Ref.[116652] Active ingredients: Orforglipron

Source: FDA, National Drug Code (US)  Revision Year: 2026 

Product description

FOUNDAYO contains orforglipron, a GLP-1 receptor agonist. The molecular formula for orforglipron calcium is C48H47F2N10O5.[0.5]Ca and the molecular weight is 902.0 g/mol. The chemical name is calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1Hindazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3c]pyridine-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}. Orforglipron calcium has the following chemical structure:

Orforglipron calcium is a white to practically white to light brown solid that is hygroscopic. Orforglipron calcium is insoluble in water.

FOUNDAYO tablets contain 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg of orforglipron (equivalent to 0.817 mg, 2.554 mg, 5.619 mg, 9.194 mg, 14.81 mg, and 17.57 mg of orforglipron calcium, respectively) as film-coated, debossed tablets for oral use. Each tablet contains the following inactive ingredients: copovidone, crospovidone, magnesium stearate, microcrystalline cellulose, and sodium carbonate anhydrous. The tablet film-coating material contains polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Additionally, the film coating of the:

  • 0.8 mg and 9 mg tablets contain ferric oxide red and ferric oxide yellow
  • 2.5 mg and 14.5 mg tablets contain ferric oxide yellow
  • 5.5 mg and 17.2 mg tablets contain ferrosoferric oxide and ferric oxide red.

Each tablet contains 10 mg or less of sodium.

Dosage Forms and Strengths

FOUNDAYO tablets are available as orforglipron:

  • 0.8 mg: pink round tablet debossed with "L" on one side and "G1" on the other side
  • 2.5 mg: light yellow round tablet debossed with "L" on one side and "G2" on the other side
  • 5.5 mg: grayish purple round tablet debossed with "L" on one side and "G3" on the other side
  • 9 mg: pink modified oval tablet debossed with "Lilly" on one side and "G4" on the other side
  • 14.5 mg: light yellow modified oval tablet debossed with "Lilly" on one side and "G5" on the other side
  • 17.2 mg: grayish purple modified oval tablet debossed with "Lilly" on one side and "G6" on the other side
How Supplied

FOUNDAYO (orforglipron) tablets are supplied in bottles with desiccant and child-resistant closure in cartons as follows:

Tablet
Strength of
Orforglipron		DescriptionPackage
Configuration		NDC
Number
0.8 mgPink round tablet debossed with "L" on o
ne side and "G1" on the other side		Bottles of 30
tablets		0002-4178-31
2.5 mgLight yellow round tablet debossed with
"L" on one side and "G2" on the other
side		Bottles of 30
tablets		0002-4503-31
5.5 mgGrayish purple round tablet debossed
with "L" on one side and "G3" on the
other side		Bottles of 30
tablets		0002-4794-31
9 mgPink modified oval tablet debossed with
"Lilly" on one side and "G4" on the other
side		Bottles of 30 tablets0002-4803-31
14.5 mgLight yellow modified oval
tablet debossed
with "Lilly" on one side and "G5" on the
other side		Bottles of 30
tablets		0002-4839-31
17.2 mgGrayish purple modified oval tablet
debossed with "Lilly" on one side and
"G6" on the other side		Bottles of 30
tablets		0002-4953-31

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA

Drugs

Drug Countries
FOUNDAYO United States
 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈